TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS’s Parkinson’s and ALS programs Cambridge, Massachusetts, Nov. 17, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN),...
https://bioadvance.com/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline/?utm_source=rss&utm_medium=rss&utm_campaign=promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline